AR089655A1 - Neurotoxinas que muestran actividad biologica acortada - Google Patents

Neurotoxinas que muestran actividad biologica acortada

Info

Publication number
AR089655A1
AR089655A1 ARP120104249A ARP120104249A AR089655A1 AR 089655 A1 AR089655 A1 AR 089655A1 AR P120104249 A ARP120104249 A AR P120104249A AR P120104249 A ARP120104249 A AR P120104249A AR 089655 A1 AR089655 A1 AR 089655A1
Authority
AR
Argentina
Prior art keywords
polypeptides
ligase
polynucleotide
polynucleotides
reason
Prior art date
Application number
ARP120104249A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48288558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089655(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR089655A1 publication Critical patent/AR089655A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un polinucleótido que codifica un polipéptido de la neurotoxina que muestra una menor duración del efecto biológico en un sujeto, en donde el polipéptido comprende al menos un motivo de reconocimiento de la ligasa E3 en la cadena liviana, en donde el motivo de reconocimiento de la ligasa E3 es, preferentemente, un motivo de fijación de la ligasa E3 MDM2. Además, polipéptidos codificados por el polinucleótido, así como polipéptidos que comprenden una o más sustituciones de aminoácidos. Vectores y células huésped que comprenden los polinucleótidos, los polipéptidos codificados por estos y los anticuerpos que se fijan específicamente a los polipéptidos. Asimismo, medicamentos que comprenden estos polinucleótidos y polipéptidos, así como a las aplicaciones terapéuticas específicas de estos. Además, métodos para la fabricación de los polipéptidos y medicamentos. Reivindicación 16: El polinucleótido de acuerdo con la reivindicación 14 o el polipéptido de acuerdo con la reivindicación 15, caracterizado porque el medicamento es para el tratamiento de una cicatrización, el tratamiento de inmovilización por fractura de huesos y ruptura de tendones, la inmovilización posquirúrgica, en especial, en relación con la hemorroidectomía, la introducción de implantes dentales, el reemplazo de la articulación de la cadera (endoprótesis), la epicondílitis, la artroplastia de rodilla, la cirugía oftalmológica, el acné, la enfermedad del intestino irritable, el vaginismo, la lumbalgia o la hiperplasia benigna de la próstata.
ARP120104249A 2011-11-09 2012-11-09 Neurotoxinas que muestran actividad biologica acortada AR089655A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161628911P 2011-11-09 2011-11-09
EP11188440 2011-11-09
US201261659137P 2012-06-13 2012-06-13
EP12171801 2012-06-13

Publications (1)

Publication Number Publication Date
AR089655A1 true AR089655A1 (es) 2014-09-10

Family

ID=48288558

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104249A AR089655A1 (es) 2011-11-09 2012-11-09 Neurotoxinas que muestran actividad biologica acortada

Country Status (18)

Country Link
US (1) US9809809B2 (es)
EP (1) EP2776457B1 (es)
JP (1) JP6162135B2 (es)
KR (1) KR20150000468A (es)
CN (1) CN103974973A (es)
AR (1) AR089655A1 (es)
AU (1) AU2012334080B2 (es)
BR (1) BR112014011137A2 (es)
CA (1) CA2855173A1 (es)
CL (1) CL2014001217A1 (es)
ES (1) ES2638333T3 (es)
HK (1) HK1199890A1 (es)
IL (1) IL232508B (es)
MX (1) MX351012B (es)
RU (1) RU2646110C2 (es)
SG (1) SG11201402131TA (es)
TW (1) TWI583792B (es)
WO (1) WO2013068476A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140377248A1 (en) * 2011-12-23 2014-12-25 Merz Pharma Gmbh & Co. Kgaa Method for the manufacturing of di-chain proteins for use in humans
CA2880897C (en) * 2012-11-21 2020-01-14 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PL2952205T3 (pl) 2014-06-06 2018-01-31 Kleiner Fisman Galit Toksyna botulinowa do zastosowania do leczenia paratonii
WO2015188944A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154635A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2015188943A1 (en) 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
WO2015188942A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
JP6772138B2 (ja) * 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
EP3590500A1 (en) 2014-12-23 2020-01-08 Merz Pharma GmbH & Co. KGaA Botulinum toxin prefilled container
RU2733493C2 (ru) * 2015-01-09 2020-10-02 Ипсен Байоинновейшн Лимитед Катионные нейротоксины
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
RU2743746C2 (ru) 2016-03-02 2021-02-25 Мерц Фарма Гмбх Энд Ко. Кгаа Композиция, содержащая ботулинический токсин
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
CN106432423B (zh) * 2016-09-21 2019-05-10 北京大学深圳研究生院 一种α-螺旋多肽及其用途
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
US11260114B2 (en) 2017-03-22 2022-03-01 Bonti, Inc. Botulinum neurotoxins for use in therapy
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) * 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US11279734B2 (en) 2017-12-01 2022-03-22 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
EP3765495A1 (en) * 2018-03-13 2021-01-20 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
CN109666683B (zh) * 2019-02-27 2021-10-29 昆明理工大学 乙酰辅酶A乙酰转移酶基因RKAcaT2及其应用
CN110721314B (zh) * 2019-10-11 2022-11-29 江苏恒泰生物科技有限公司 一种抗肿瘤纳米药物及其制备方法
SE2050326A1 (en) * 2020-03-25 2021-06-29 Jonathan Davies Engineered botulinum neurotoxin serotype E
CN111763663B (zh) * 2020-07-09 2022-04-15 昆明理工大学 一种天麻葡糖基转移酶基因及应用
CN112410321B (zh) * 2020-11-26 2022-01-28 昆明理工大学 一种β-葡萄糖苷酶Ttbgl3及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500365A (ja) * 1996-07-05 2001-01-16 ノバルティス アクチエンゲゼルシャフト Ｐ５３とｍｄｍ２の間の相互作用の阻害剤
GB9708089D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7879341B2 (en) 2004-07-26 2011-02-01 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
WO2008106507A2 (en) * 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
US8598321B2 (en) * 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2008157374A1 (en) * 2007-06-13 2008-12-24 The United States Of America, As Represented By The Secretrary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type a
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
FR2924721B1 (fr) * 2007-12-10 2010-02-26 Cytomics Systems Procede de criblage d'agents modulant l'activite de l'ubiquitine ligase mdm2 et moyens destines a la mise en oeuvre dudit procede
US8343743B2 (en) * 2008-06-10 2013-01-01 Synaptic Research, Llc Designer ubiquitin ligases having a non-cleavable SNAP25 domain and E3-ligase domain
US20100278826A1 (en) * 2008-06-10 2010-11-04 Shoemaker Charles B Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity

Also Published As

Publication number Publication date
RU2646110C2 (ru) 2018-03-01
TW201326390A (zh) 2013-07-01
CA2855173A1 (en) 2013-05-16
WO2013068476A1 (en) 2013-05-16
RU2014123060A (ru) 2015-12-20
IL232508A0 (en) 2014-06-30
ES2638333T3 (es) 2017-10-19
BR112014011137A2 (pt) 2018-06-12
AU2012334080B2 (en) 2016-12-15
MX351012B (es) 2017-09-28
EP2776457A1 (en) 2014-09-17
JP6162135B2 (ja) 2017-07-12
TWI583792B (zh) 2017-05-21
CN103974973A (zh) 2014-08-06
US20140308267A1 (en) 2014-10-16
US9809809B2 (en) 2017-11-07
IL232508B (en) 2018-06-28
CL2014001217A1 (es) 2014-10-10
JP2014533945A (ja) 2014-12-18
AU2012334080A1 (en) 2014-05-15
SG11201402131TA (en) 2014-08-28
EP2776457B1 (en) 2017-08-02
HK1199890A1 (en) 2015-07-24
KR20150000468A (ko) 2015-01-02
MX2014005544A (es) 2014-05-30

Similar Documents

Publication Publication Date Title
AR089655A1 (es) Neurotoxinas que muestran actividad biologica acortada
Kon et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis
Andia et al. Current concepts and translational uses of platelet rich plasma biotechnology
Perdisa et al. Adipose‐derived mesenchymal stem cells for the treatment of articular cartilage: a systematic review on preclinical and clinical evidence
Mishra et al. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation
RU2012103376A (ru) Биологическая активность
Singh Mohal et al. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications
De La Mata Platelet rich plasma. A new treatment tool for the rheumatologist?
Valerio et al. The use of urinary bladder matrix in the treatment of trauma and combat casualty wound care
Abate et al. Platelet rich plasma in tendinopathies: how to explain the failure
Koga et al. Topical cutaneous CO2 application by means of a novel hydrogel accelerates fracture repair in rats
Fleming et al. Regenerative medicine applications in combat casualty care
Dunn et al. Biomimetic sponges improve functional muscle recovery following composite trauma
Ho et al. Refining the indications for scapula tip in mandibular reconstruction
Zhao et al. Supramolecular hydrogel based on an osteogenic growth peptide promotes bone defect repair
Bumbaširević et al. Mangled extremity-modern concepts in treatment
Fan et al. Combined treatment with extracorporeal shock‑wave therapy and bone marrow mesenchymal stem cell transplantation improves bone repair in a rabbit model of bone nonunion Retraction in/10.3892/mmr. 2018.9374
M. Mhashilkar et al. Advent and maturation of regenerative medicine
Saunders et al. Regenerative rehabilitation of catastrophic extremity injury in military conflicts and a review of recent developmental efforts
Hirche et al. Novel use of a flowable collagen–glycosaminoglycan matrix (Integra™ Flowable Wound Matrix) combined with percutaneous cannula scar tissue release in treatment of post-burn malfunction of the hand—A preliminary 6 month follow-up
Piaggesi et al. New technololgies for tissue replacement: Highlighting technologies for surgical management of chronic wounds
Keeling et al. Strategies for managing massive defects of the foot in high-energy combat injuries of the lower extremity
Simental-Mendía et al. Platelet-rich plasma in knee osteoarthritis treatment
Hauzeur et al. Phases 1–3 clinical trials using adult stem cells in osteonecrosis and nonunion fractures
Abu-Seida Regenerative therapy for equine osteoarthritis: A concise review

Legal Events

Date Code Title Description
FB Suspension of granting procedure